Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8892 in Pulmonary Hypertension and Left Heart Disease
NCT02078557Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- May 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of MK-8892 in pulmonary hypertension (PH) and heart failure with reduced ejection fraction (HFrEF), sponsored by Merck & Co. Primary endpoints: Percentage Change From Baseline in Pulmonary Vascular Resistance at Day 28, Number of Participants Who Experienced an Adverse Event up to 42 days and 1 more. Started May 2014; status: terminated.
02
Drugs
MK-8892
03
Conditions
pulmonary hypertension (PH)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02078557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078557.